PATH vs RCUS
Uipath Inc (PATH) versus Arcus Biosciences Inc (RCUS) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Arcus Biosciences Inc (RCUS) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported RCUS revenue for 2024-12-31 was $258.0M. Net income was -$283.0M. Revenue was up 120.5% from 2023-12-31 to 2024-12-31. RCUS currently screens at market cap $885.2M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. RCUS currently screens at market cap $885.2M.
Not investment advice. Open the PATH and RCUS stock pages for the full models.
Not investment advice.